Patents Assigned to RHEINISCHE FRIEDRICH-WILHELMS UNIVERSITÄT BONN
  • Patent number: 11291675
    Abstract: The present invention relates to 6?-sialyllactose and/or pharmaceutically acceptable salts thereof for use in the treatment of a disease selected from hearing loss and hearing loss—associated tinnitus.
    Type: Grant
    Filed: December 7, 2018
    Date of Patent: April 5, 2022
    Assignee: Rheinische Friedrich-Wilhelms-Universität Bonn
    Inventors: Harald Neumann, Christine Klaus, Anahita Shahraz
  • Publication number: 20220073921
    Abstract: The present invention relates to an aptamer comprising a nucleotide sequence SEQ ID NO: 1 or a fragment thereof of at least 20 contiguous nucleotides of the nucleotide sequence SEQ ID NO: 2, wherein the aptamer comprises a polyethylene glycol (PEG) moiety conjugated to the 5? or the 3? end. The invention further relates to a composition comprising the aptamer, and the use of the aptamer in the diagnosis and treatment of cancer, particularly hormone refractory prostate tumours.
    Type: Application
    Filed: January 20, 2020
    Publication date: March 10, 2022
    Applicant: RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITÄT BONN
    Inventors: Frédéric DUCONGÉ, Andreas LINGNAU, Holger WEBER, Michael KUBBUTAT, Günter MAYER
  • Patent number: 11142763
    Abstract: The present invention relates to new triphosphate-modified oligonucleotides which may act as RIG-I ligands as well as a new method allowing the synthesis and purification in high yield and purity suitable for pharmaceutical applications.
    Type: Grant
    Filed: May 2, 2018
    Date of Patent: October 12, 2021
    Assignee: RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITÄT BONN
    Inventors: Marion Goldeck, Jasper Van Den Boorn, János Ludwig, Christine Schuberth-Wagner
  • Publication number: 20210310004
    Abstract: The invention relates to a method of identifying or producing an aptamer, the method comprising the steps of: a) Providing a candidate mixture of nucleic acids; b) Contacting the candidate mixture with a target sample; c) Partitioning nucleic acids that bind to the target sample from those that do not bind; d) Amplifying the binding nucleic acids to produce a population of nucleic acids that bind the target sample; e) Single strand displacement of the amplified nucleic acids, f) optionally repeating the steps a) to e), thereby identifying or producing an aptamer, wherein the target sample provides one or more peptides and/or proteins in a denatured form.
    Type: Application
    Filed: July 29, 2019
    Publication date: October 7, 2021
    Applicant: RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITÄT BONN
    Inventors: Günter MAYER, Nora KARNOWSKI, Maren HAMANN, Tjasa LEGEN
  • Patent number: 11110124
    Abstract: The present invention pertains to extracellular vesicles (exosomes) that are produced by culturing tumor cells in the presence of various ligands or activators of innate immunity receptors and subsequently isolating and purifying the vesicles in the culture supernatant. The invention provides also pharmaceutical compositions comprising the inventive exosomes. The exosomes of the invention are provided as medicaments for example in the treatment of cancer diseases.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: September 7, 2021
    Assignee: RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAET BONN
    Inventors: Christoph Coch, Juliane Dassler-Plenker, Gunther Hartmann
  • Publication number: 20210238818
    Abstract: The invention relates to a device for taking up oil from a water surface, comprising a container for receiving the oil and an oil-transporting means, wherein a portion of the oil-transporting means can be brought into fluid communication with the water surface and another portion of the oil-transporting means is disposed within the container, wherein the oil can be transported into the container via the oil-transporting means, wherein the oil-transporting means is formed from a hydrophobic fabric, the surface of which comprises filament-shaped and/or grid-like structures which are designed in such a way that they retain a gas layer on the surface of the hydrophobic fabric under water. The invention further relates to a corresponding method for taking up oil from a water surface.
    Type: Application
    Filed: July 25, 2019
    Publication date: August 5, 2021
    Applicant: RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITÄT BONN
    Inventors: Wilhelm BARTHLOTT, Markus MOOSMANN, Matthias MAIL
  • Publication number: 20200289537
    Abstract: The present invention relates to 6?-sialyllactose and/or pharmaceutically acceptable salts thereof for use in the treatment of a disease selected from hearing loss and hearing loss—associated tinnitus.
    Type: Application
    Filed: December 7, 2018
    Publication date: September 17, 2020
    Applicant: Rheinische Friedrich-Wilhelms-Universität Bonn
    Inventors: Harald NEUMANN, Christine KLAUS
  • Publication number: 20200208184
    Abstract: A method of producing 5-ketofructose using an acetic acid bacterium which is genetically modified to express a fructose dehydrogenase as well as to microorganisms which can be used in said method.
    Type: Application
    Filed: June 13, 2018
    Publication date: July 2, 2020
    Applicants: RWTH Aachen, Forschungszentrum Jülich GmbH, Rheinische Friedrich-Wilhelms-Universität Bonn
    Inventors: Elena Herweg, Jochen Büchs, Michael Bott, Ines Kiefler, Uwe Deppenmeier, Konrad Kosciow, Anna Siemen
  • Publication number: 20200123547
    Abstract: The present invention relates to a nucleic acid-based assembly comprising: at least one nucleic acid aptamer, and at least one nucleic acid motif designed to physically capture a drug. The nucleic acid motif may comprise one or more photo-responsive moieties that effect the release of the drug upon irradiation. The aptamer and the nucleic acid motif each can be covalently linked to one or more lipids, and the lipid-modified aptamer and nucleic acid motif may form the assembly through noncovalent interaction. The invention further relates to use of the nucleic acid-based assembly in the treatment of cancer.
    Type: Application
    Filed: December 7, 2017
    Publication date: April 23, 2020
    Applicant: Rheinische Friedrich-Wilhelms-Universität Bonn
    Inventors: Michael FAMULOK, Deepak PRUSTY, Adam VOLKER, Stephan IRSEN
  • Patent number: 10238682
    Abstract: Oligonucleotides bearing free, uncapped 5? phosphate group(s) are recognized by RIG-I, leading to the induction of type I IFN, IL-18 and IL-1? production. Bacterial RNA also induces type I IFN production. 5? phosphate oligonucleotides and bacterial RNA can be used for inducing an anti-viral response or an anti-bacterial response, in particular, type I IFN and/or IL-18 and/or IL-1? production, in vitro and in vivo and for treating various disorders and diseases such as viral infections, bacterial infections, parasitic infections, tumors, allergies, autoimmune diseases, immunodeficiencies and immunosuppression. Single-stranded 5? triphosphate RNA can be used for inducing an anti-viral response, an anti-bacterial response, or an anti-tumor response, in particular, type I IFN and/or IL-18 and/or IL-1? production, in a target cell-specific manner.
    Type: Grant
    Filed: November 9, 2015
    Date of Patent: March 26, 2019
    Assignee: Rheinische Friedrich-Wilhelms-Universität Bonn
    Inventors: Gunther Hartmann, Veit Hornung
  • Patent number: 10196638
    Abstract: The present invention provides an oligonucleotide which is capable of activating RIG-I and inducing an anti-viral, in particular, an IFN, response in cells expressing RIG-I. The present invention further provides an oligonucleotide which is capable of activating RIG-I and which has target gene-silencing activity. The oligonucleotide of the present invention has a double-stranded section of at least 19, preferably at least 21 bp, at least one 5? triphosphate, and at least one blunt end which bears a 5? triphosphate. The present invention further provides the use said oligonucleotide for inducing an anti-viral, in particular, an IFN, response in vitro and in vivo. The present invention additionally provides the use of said oligonucleotide for preventing and/or treating diseases or conditions such as infections, tumors/cancers, and immune disorders.
    Type: Grant
    Filed: May 10, 2016
    Date of Patent: February 5, 2019
    Assignee: Rheinische Friedrich-Wilhelms-Universität Bonn
    Inventors: Gunther Hartmann, Martin Schlee
  • Patent number: 10174326
    Abstract: The present invention provides a TLR7 ligand and its use in therapeutic applications. Specifically, the present application provides a RNA oligonucleotide comprising a G:U wobble base pair in the context of a fully double-stranded structure and its use in treating disease such as viral infections, immune disorders and cancer.
    Type: Grant
    Filed: March 17, 2010
    Date of Patent: January 8, 2019
    Assignee: Rheinische Friedrich-Wilhelms-Universität Bonn
    Inventors: Gunther Hartmann, Winfried Barchet, Vera Wimmenauer
  • Publication number: 20180362118
    Abstract: Device mountable on a surface (10), the device comprising a spacer system (12, 16, 20, 22) and a grid structure (2) which grid structure (2) is attached in spaced relation to the surface (10) by means of the spacer system (12, 16, 20, 22), wherein the distance between the surface (10) and the grid structure (2) is in a range from >0.1 ?m to <10 mm, wherein the grid structure (2) forms meshes of a mesh size in a range from >0.5 ?m to <8 mm, and wherein the surface of the grid structure (2) is at least partially amphiphobic. Method of maintaining a gas or air layer on a surface when the surface is immersed in a liquid or water comprising such device, and uses thereof.
    Type: Application
    Filed: December 21, 2016
    Publication date: December 20, 2018
    Applicant: RHEINISCHE FRIEDRICH-WILHELMS UNIVERSITÄT BONN
    Inventors: Wilhelm Barthlott, Birte Böhnlein, Matthias Mail
  • Publication number: 20180312841
    Abstract: The present invention relates to new triphosphate-modified oligonucleotides which may act as RIG-I ligands as well as a new method allowing the synthesis and purification in high yield and purity suitable for pharmaceutical applications.
    Type: Application
    Filed: May 2, 2018
    Publication date: November 1, 2018
    Applicant: RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITÄT BONN
    Inventors: Marion GOLDECK, Jasper VAN DEN BOORN, János LUDWIG, Christine SCHUBERTH-WAGNER
  • Patent number: 10072262
    Abstract: The present invention relates to new triphosphate-modified oligonucleotides which may act as RIG-I ligands as well as a new method allowing the synthesis and purification in high yield and purity suitable for pharmaceutical applications.
    Type: Grant
    Filed: March 27, 2015
    Date of Patent: September 11, 2018
    Assignee: Rheinische Friedrich-Wilhelms-Universität Bonn
    Inventors: Marion Goldeck, Jasper Van Den Boorn, János Ludwig, Christine Schuberth-Wagner
  • Patent number: 10059943
    Abstract: The present invention relates to new triphosphate-modified oligonucleotides which may act as RIG-I ligands as well as a new method allowing the synthesis and purification in high yield and purity suitable for pharmaceutical applications.
    Type: Grant
    Filed: September 26, 2013
    Date of Patent: August 28, 2018
    Assignee: Rheinische Friedrich-Wilhelms-Universität Bonn
    Inventors: Marion Goldeck, Jasper Van Den Boorn, János Ludwig, Christine Schuberth-Wagner
  • Patent number: 10036021
    Abstract: The present invention provides an oligonucleotide which is capable of activating RIG-I and inducing an anti-viral, in particular, an IFN, response in cells expressing RIG-I. The present invention further provides an oligonucleotide which is capable of activating RIG-I and which has target gene-silencing activity. The oligonucleotide of the present invention has a double-stranded section of at least 19, preferably at least 21 bp, at least one 5? triphosphate, and at least one blunt end which bears a 5? triphosphate. The present invention further provides the use said oligonucleotide for inducing an anti-viral, in particular, an IFN, response in vitro and in vivo. The present invention additionally provides the use of said oligonucleotide for preventing and/or treating diseases or conditions such as infections, tumors/cancers, and immune disorders.
    Type: Grant
    Filed: May 10, 2016
    Date of Patent: July 31, 2018
    Assignee: Rheinische Friedrich-Wilhelms-Universität Bonn
    Inventors: Gunther Hartmann, Martin Schlee
  • Patent number: 9944721
    Abstract: The present invention relates to a branched or unbranched free or glycosidically bound polysialic acid according to general formula (1) as given as follows poly-(?(2?8 or 2?9)Neu5Ac)n (1) wherein Neu5Ac is N-acetylneuraminic acid, and n is an integer in the range from 14 to 26 and/or pharmaceutically acceptable salts thereof, a polysaccharide composition comprising the polysialic acid (1), and the use as a medicament, particularly in the therapeutic and/or prophylactic treatment of degenerative, demyelinating and inflammatory diseases of the central nervous system, and degenerative or inflammatory retinal diseases.
    Type: Grant
    Filed: March 18, 2014
    Date of Patent: April 17, 2018
    Assignees: RHEINISCHE FRIEDRICH-WILHELMS UNIVERSITÄT BONN, UNIVERSITÄT ZU KÖLN
    Inventors: Harald Neumann, Jens Kopatz, Anahita Shahraz, Marcus Karlstetter, Thomas Langmann
  • Patent number: 9896689
    Abstract: The present invention relates to a method of preparing triphosphate-modified oligonucleotides using a capture tag. The method allows the synthesis and purification of triphosphate-modified oligonucleotides in high yield and purity suitable for pharmaceutical applications.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: February 20, 2018
    Assignee: Rheinische Friedrich-Wilhelms-Universität Bonn
    Inventors: Janos Ludwig, Marion Goldeck, Brian Sproat
  • Patent number: 9790507
    Abstract: The present invention relates to an aptamer comprising a nucleotide sequence SEQ ID NO: 1, a composition comprising an aptamer, and the use of the aptamer in the diagnosis and treatment of cancer, particularly solid tumors.
    Type: Grant
    Filed: May 26, 2014
    Date of Patent: October 17, 2017
    Assignee: RHEINISCHE FRIEDRICH-WILHELMS UNIVERSITÄT BONN
    Inventors: Günter Mayer, Ursula Maria Katia Schöler, Mohammad Seyed Taghdisi Heidarian